ArrePath | AP-001 | 3a | NME | E. coli, K. pneumoniae, Enterobacter spp., Citrobacter spp., Other Enterobacterales, Salmonella spp., Shigella spp., E. faecium, N. gonorrhoeae, H. influenzae / Complicated urinary tract infections (cUTI) | Lead opt |
Tabrix | anti-virulence agents | 3a | NME | Mycobacterium tuberculosis / Cystic fibrosis associated infections | IND/CTA ready |
Granulytics | Undisclosed | 3a | Protein/Peptide | E. coli, S. aureus | Pre-clinical |
Santero Therapeutics | SAN-Sa1 | 3a | NME | S. aureus | Pre-clinical |
Ultupharma AB | ULT1 | 3a | NME | E. faecium, S. aureus, S. pneumoniae, Group A Streptococci / Complicated urinary tract infections (cUTI) | IND/CTA ready |
Ultupharma AB | ULT2C | 3a | NME | E. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., S. aureus, S. pneumoniae, H. influenzae, Group A Streptococci /Skin and Skin-structure infections (ABSSSI) | IND/CTA ready |
Ultupharma AB | ULT2B | 3a | NME | E. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp., H. influenzae / Cystic fibrosis associated infections | IND/CTA ready |
Ultupharma AB | ULT2A | 3a | NME | E. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp., S. aureus, H. influenzae / Cystic fibrosis associated infections | IND/CTA ready |
Ultupharma AB | ULT3 | 3a | Protein/Peptide | A. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Other Enterobacterales, P. aeruginosa / Skin and Skin-structure infections (ABSSSI) | IND/CTA ready |
VAXDYN | AcinetoVax | 1a | Vaccine | A. baumannii / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Pre-clinical |
VAXDYN | EcoVax | 1a | Vaccine | A. baumannii, E. coli / Bloodstream infections | Pre-clinical |
VAXDYN | P-Vax | 1a | Vaccine | A. baumannii / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Pre-clinical |
VAXDYN | K-Vax | 1a | Vaccine | A. baumannii, K. pneumoniae / Bloodstream infections | IND/CTA ready |
Epynext Therapeutics | EPY-001 | 3a | Antibody | P. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Lead opt |
Arivin therapeutics | Viri-2425 | 3a | NME | K. pneumoniae, P. aeruginosa / Chronic open wounds | Pre-clinical |
Arivin therapeutics | Viri-01 | 3a | NME | K. pneumoniae, P. aeruginosa / Cystic fibrosis associated infections | Pre-clinical |
Thioredoxin Systems AB | EbsArgent | 3a | NME | A. baumannii, P. aeruginosa, S. aureus / Complicated urinary tract infections (cUTI) | IND/CTA ready |
BioNTech R&D | BNT331 | 3a | Protein/Peptide | Bacterial Vaginosis | IND/CTA ready |
Basilea | Novel target | 3a | NME | E. faecium, S. aureus, S. pneumoniae / Osteomyelitis | Lead opt |
Basilea | Novel target (LptA inhibitor) | 3a | NME | Other Enterobacterales (carbapenem-resistant) / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Lead opt |
Nexbiome Therapeutics | BGA-1901 | 3a | Antibody | H. pilori | Pre-clinical |
Nexbiome Therapeutics | BGY-1601 | 3a | Antibody | Candida spp and G. vaginalis | IND/CTA ready |
Nexbiome Therapeutics | NIN-2101 | 3a | Protein/Peptide | Enterococcus faecium, S. aureus / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP) | Lead opt |
SurvivX | SUR-101 | 3c | NME | Immune-oncology / Sepsis | IND/CTA ready |
Infex Therapeutics Ltd | GON-X | 3a | NME | N. Gonorrhoeae / Resistant Neisseria Gonorrhoea | Lead opt |
Infex Therapeutics Ltd | VAP-X | 4a | NME | P. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP) | Lead opt |
Disperazol Pharma ApS | Disperazol | 3d | NME | P. aeruginosa / Complicated urinary tract infections (cUTI) | Pre-clinical |
Disperazol Pharma ApS | Disperazol | 1b | NME | P. aeruginosa / Complicated urinary tract infections (cUTI) | Pre-clinical |
Osta Therapeutics | Osta 27 | | Other | A. baumannii, P. aeruginosa, M. tuberculosis / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Pre-clinical |
AUROBAC THERAPEUTICS | ATX401 | 3a | Protein/Peptide | Gram-negative pathogens / Treatment of HAP/VAP caused by Gram-negative bacteria as 1st line therapy suppressing AMR emergence | Pre-clinical |
AUROBAC THERAPEUTICS | ATX101 | 4a | NME | Treatment of early septic shock to prevent progression and improve outcome | Pre-clinical |
NanoReviv | Staph-EX | 3a | Other | S. aureus, Group A Streptococci, Group B Streptococci / Skeletal Infections | Pre-clinical |
PHAXIAM | PHAXIAM NA | 3a | Phage | Diabetic foot ulcer with anti S.aureus phage therapy | Pre-clinical |
PHAXIAM | PHAXIAM NA | 3a | Phage | Hospital acquired or ventilator- acquired bacterial pneumoniae with anti-P.aeruginosa Phage therapy | Pre-clinical |
PHAXIAM | PP970, PP1002, PP1151, PP2000 | 3a | Phage | Complicated Urinary Tract Infection (cUTI) with anti-E. coli phage therapy | IND/CTA ready |
PHAXIAM | PP1493/PP1815 | 3a | Phage | Endocarditis with anti-S.aureus phage therapy | Phase I |
PHAXIAM | PP1493/PP1815 | 3a | Phage | Prosthetic Joint Infection (PJI) with anti-S.aureus phage therapy | Phase II |
discoveric bio beta | NIDB-3002 | 3a | NME | P. aeruginosa / Cystic fibrosis associated infections | Lead opt |
discoveric bio beta | NIDB-3001 | 3a | NME | E. coli, K. pneumoniae / Bloodstream infections | Lead opt |
Omnix Medical | OMN71 | 3a | Protein/Peptide | Salmonella spp., S. aureus / Skin and Skin-structure infections (ABSSSI) | Pre-clinical |
Omnix Medical | OMN51 | 3a | Protein/Peptide | Enterobacter spp., P. aeruginosa, S. aureus / Cystic Fibrosis associated infections | Pre-clinical |
Destiny Pharma plc | XF-73 | 1b | NME | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Prevention of oral mucositis | Pre-clinical |
Destiny Pharma plc | XF-73 | 3a | NME | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Burns | Pre-clinical |
Destiny Pharma plc | XF-73 | 3a | NME | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Treatment of chronic rhinosinusitis | Pre-clinical |
Destiny Pharma plc | XF-73 | 3a | NME | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Cystic fibrosis associated infections | Pre-clinical |
Destiny Pharma plc | XF-73 | 3a | NME | Staphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Prevention of post-surgical infection | Phase II |
Destiny Pharma plc | NTCD-M3 | 1b | NME | Toxigenic strains of C. difficile / Prevention of recurrence of C diff infection | Phase II |
Destiny Pharma plc | SPOR-COV | 1a | NME | Respiratory viruses, SARS-COV-2 & Influenza / Prevention of viral respiratory infections | Pre-clinical |
Infex Therapeutics Ltd | RESP-X | 3c | Antibody | P. aeruginosa / Non-cystic-fibrosis bronchiectasis | Phase II |
Infex Therapeutics Ltd | MET-X | 3d | NME | A. baumannii, P. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP) | IND/CTA ready |
Infex Therapeutics Ltd | RDX-02 | 3a | NME | Gram-negative AMR infections | Lead opt |
AdjuTec Pharma AS | APC247 | 3d | NME | E. coli, K. pneumoniae / Complicated urinary tract infections (cUTI) | IND/CTA ready |
F2G Ltd | Olorofim | 3a | NME | DHODH inhibitor/Aspergillosis refractory, resistant or intolerant; Lomentospora prolificans, Scedosporium, Fusarium and Scopulariopsis species; Coccidioidomycosis refractory | Phase III |
AdjuTec Pharma AS | APC148 | 3d | NME | K. pneumoniae; Enterobacter spp / complicated urinary tract infections (cUTI) | Phase I |
OLGRAM | Ol20-01 | 5a | Protein/Peptide | P. aeruginosa; Broad-spectrum G+/G-/Cystic fibrosis associated infections | Pre-clinical |
Selmod GmbH | slm 500 | 3a | NME | Escherichia coli; Broad-spectrum G+/G-/Complicated urinary tract infections (cUTI) | Pre-clinical |
Selmod GmbH | slm 400 | 3a | NME | A. baumannii; Broad-spectrum G+/G-/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Pre-clinical |
Selmod GmbH | slm 300 | 3a | NME | Klebsiella pneumoniae; Broad-spectrum G+/G-/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Pre-clinical |
Selmod GmbH | slm 200 | 3a | Protein/Peptide | Candida albicans, Aspergillus fumigatus, Candida auris/Invasive aspergillosis, Oral Candidiasis, Bronchopulmonary aspergillosis | Lead opt |
Selmod GmbH | slm 100 | 3a | NME | Candida albicans, Aspergillus fumigatus, Candida auris/Invasive aspergillosis, Oral Candidiasis, Bronchopulmonary aspergillosis | Lead opt |
Assuré Medical Limited | Sol-UTI | 1b | Other | P. aeruginosa, S.aureus / Uncomplicated urinary tract infections (uUTI) | Pre-clinical |
BioVersys AG | BV100 | 3a | NME | A. baumannii/HAP, VAP, BSI | Phase I |
ABAC therapeutics | ABAC-40244 | 3a | NME | Staphylococcus aureus/Hospital infections | Lead opt |
ABAC therapeutics | ABAC-40411 | 3a | NME | Streptococcus pneumoniae/Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc) | Lead opt |
ANTABIO S.A.S | SBLi (ANT3310) | 3d | NME | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | IND/CTA ready |
VibioSphen | VIKYNG | 3a | Other | A. baumannii, P. aeruginosa, S. aureus / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | IND/CTA ready |
QureTech Bio AB | GmP | 3a | NME | E. faecium, S. aureus / Skin and Skin-structure infections (ABSSSI) | Lead opt |
QureTech Bio AB | MTI | 3a | NME | Mycobacterium tuberculosis / Tuberculosis | Lead opt |
Omnix Medical | OMN6 | 3a/5a | Protein/Peptide | A. baumannii, P. aeruginosa, E. coli, K. pneumoniae; Enterobacter spp / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Phase I |
Northern Antibiotics Oy (Ltd) | NAB815 | 3a | Protein/Peptide | A. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp. / Complicated urinary tract infections (cUTI) | Lead opt |
Northern Antibiotics Oy (Ltd) | NAB739 | 3a | Protein/Peptide | A. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp. / Complicated urinary tract infections (cUTI) | Lead opt |
tamrisa | 2G-DAB | 3a | NME | Enterobacterales, P. aeruginosa, A. baumannii/Complicated urinary tract infections (cUTI) | Lead opt |
tamrisa | EBL-1463 | 3a | NME | Enterobacterales/Complicated urinary tract infections (cUTI) | Pre-clinical |
IMMUNETHEP, SA | Unimab | 3c | Antibody | Escherichia coli; Klebsiella pneumoniae; Staphylococcus aureus; Streptococcus pneumoniae; S. agalactiae/Bloodstream infections | Pre-clinical |
IMMUNETHEP, SA | PNV | 1a | Vaccine | S. aureus, E. Coli, ETEC/Bloodstream infections, Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc) | Pre-clinical |
Hypharm GmbH | HY-133 | 1b | Phage | Staphylococcus aureus/Nasal colonization with MRSA | Phase I |
Eligo Bioscience | EB004 | 1b | Phage | Escherichia coli; Klebsiella pneumoniae/Bloodstream infections | Pre-clinical |
Debiopharm International | Debio 1453 | 3a | NME | Neisseria gonorrhoeae / Gonorrhoea | IND/CTA ready |
Debiopharm International | Afabicin | 3a | NME | Staphylococcus spp./ABSSSI (caused by S. aureus), bone and joint infections | Phase II |
Combioxin SA | CAL02 | 4a | Other | Virulence factors, broad spectrum Gram+ and Gram-, resistance agnostic/Severe community-acquired bacterial pneumonia | Phase II |
Centauri Therapeutics Ltd | ABX01 | 3c | Other | A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp./Healthcare-asscoiated infections | Pre-clinical |
Centauri Therapeutics Ltd | ABX02 | 3c | Other | P. aeruginosa/Healthcare-asscoiated infections | Pre-clinical |
BioVersys AG | BV200 | 4a | NME | Staphylococcus aureus/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Lead opt |
BioVersys AG | BV300 | 3a | NME | A. baumannii; P. aeruginosa; Enterobacter spp.; Staphylococcus aureus; Enterococcus faecium/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | Lead opt |
BioVersys AG | BVL-GSK098 | 3d | NME | M. tuberculosis/Tuberculosis | Phase I |
Basilea | Ceftobiprole | 3a | NME | S. aureus (including MRSA); Streptococcus spp; Enterococcus faecalis; Enterobacterales; P. aeruginosa / Staphylococcus aureus bacteremia; Acute bacterial skin and skin structure infections | Phase III |
Basilea | Ceftobiprole | 3a | NME | S. aureus (including MRSA); Streptococcus spp; Enterococcus faecalis; Enterobacterales; P. aeruginosa; Haemophilus influenzae / CAP, HAP | Marketed |
ANTABIO S.A.S | PEi (ANT3273) | 3c | NME | P. aeruginosa / Non-CF bronchiectasis associated infections | Pre-clinical |
ANTABIO S.A.S | MBLi (ANT2681) | 3d | NME | Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Complicated urinary tract infections (cUTI) | IND/CTA ready |
ALLECRA THERAPEUTICS | Cefepime / Enmetazobactam | 3d | NME | cUTI, AP | Phase III |
Akthelia | AKT-011 | 3c | NME | E. coli, Salmonella spp / Febrile Neutropenia | Pre-clinical |
ABAC therapeutics | ABAC-39877 | 3a | NME | A. baumannii/Hospital infections | Pre-clinical |